Your browser doesn't support javascript.
loading
Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
Vaz-Luis, Ines; Di Meglio, Antonio; Havas, Julie; El-Mouhebb, Mayssam; Lapidari, Pietro; Presti, Daniele; Soldato, Davide; Pistilli, Barbara; Dumas, Agnes; Menvielle, Gwenn; Charles, Cecile; Everhard, Sibille; Martin, Anne-Laure; Cottu, Paul H; Lerebours, Florence; Coutant, Charles; Dauchy, Sarah; Delaloge, Suzette; Lin, Nancy U; Ganz, Patricia A; Partridge, Ann H; André, Fabrice; Michiels, Stefan.
Afiliación
  • Vaz-Luis I; Gustave Roussy, Medical Oncology, Villejuif, France.
  • Di Meglio A; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Havas J; Gustave Roussy, Medical Oncology, Villejuif, France.
  • El-Mouhebb M; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Lapidari P; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Presti D; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Soldato D; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Pistilli B; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Dumas A; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Menvielle G; Gustave Roussy, Medical Oncology, Villejuif, France.
  • Charles C; INSERM Unit 981-Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Everhard S; Universite de Paris, ECEVE UMR 1123, INSERM, Paris, France.
  • Martin AL; Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.
  • Cottu PH; Gustave Roussy, Supportive Care, IPLESP, Paris, France.
  • Lerebours F; UNICANCER, Paris, France.
  • Coutant C; UNICANCER, Paris, France.
  • Dauchy S; Institut Curie, Paris, France.
  • Delaloge S; Institut Curie Saint Cloud, Saint Cloud, France.
  • Lin NU; Centre Georges-François Leclerc, Dijon, France.
  • Ganz PA; Gustave Roussy, Supportive Care, IPLESP, Paris, France.
  • Partridge AH; Gustave Roussy, Medical Oncology, Villejuif, France.
  • André F; Dana-Farber Cancer Institute, Boston, MA.
  • Michiels S; University of California, Los Angeles, CA.
J Clin Oncol ; 40(19): 2148-2162, 2022 07 01.
Article en En | MEDLINE | ID: mdl-35290073
PURPOSE: Fatigue is recognized as one of the most burdensome and long-lasting adverse effects of cancer and cancer treatment. We aimed to characterize long-term fatigue trajectories among breast cancer survivors. METHODS: We performed a detailed longitudinal analysis of fatigue using a large ongoing national prospective clinical study (CANcer TOxicity, ClinicalTrials.gov identifier: NCT01993498) of patients with stage I-III breast cancer treated from 2012 to 2015. Fatigue was assessed at diagnosis and year 1, 2, and 4 postdiagnosis. Baseline clinical, sociodemographic, behavioral, tumor-related, and treatment-related characteristics were available. Trajectories of fatigue and risk factors of trajectory-group membership were identified by iterative estimates of group-based trajectory models. RESULTS: Three trajectory groups were identified for severe global fatigue (n = 4,173). Twenty-one percent of patients were in the high-risk group, having risk estimates of severe global fatigue of 94.8% (95% CI, 86.6 to 100.0) at diagnosis and 64.6% (95% CI, 59.2 to 70.1) at year 4; 19% of patients clustered in the deteriorating group with risk estimates of severe global fatigue of 13.8% (95% CI, 6.7 to 20.9) at diagnosis and 64.5% (95% CI, 57.3 to 71.8) at year 4; 60% were in the low-risk group with risk estimates of 3.6% (95% CI, 2.5 to 4.7) at diagnosis and 9.6% (95% CI, 7.5 to 11.7) at year 4. The distinct dimensions of fatigue clustered in different trajectory groups than those identified by severe global fatigue, being differentially affected by sociodemographic, clinical, and treatment-related factors. CONCLUSION: Our findings highlight the multidimensional nature of cancer-related fatigue and the complexity of its risk factors. This study helps to identify patients with increased risk of severe fatigue and to inform personalized interventions to ameliorate this problem.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos